- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03958435
Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery
July 14, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
Background:
- . The incidence and mortality of colon cancer are high in China and in the world.
- . The treatment of many patients in the real world is not standardized, and there are problems such as over-treatment or under-treatment. To explore the adjuvant treatment of colon cancer in the Chinese population, this study will retrospectively analyze real-world data on adjuvant therapy for colon cancer in Chinese patients after radical surgery.
The purpose of research:
- . Current status of adjuvant therapy for stage II-III colon cancer in the real world: chemotherapy regimen, chemotherapy time, efficacy, safety, etc.
- . Comparison of efficacy and safety of different adjuvant chemotherapy time (<3 months vs. >=3 months) in high-risk stage II and III colon cancer patients in the real world
- . Comparison of efficacy and safety of different adjuvant chemotherapy regimens (XELOX vs. FOLFOX) in high-risk stage II and III colon cancer patients in the real world
Study Overview
Status
Recruiting
Study Type
Observational
Enrollment (Anticipated)
20000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ying Yuan, Ph.D&MD
- Phone Number: +86-571-87784795
- Email: yuanying1999@zju.edu.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Recruiting
- Jiangsu Province People Hospital
-
Contact:
- Yanhong Gu, MD
-
-
Shanghai
-
Shanghai, Shanghai, China
- Recruiting
- Changhai Hospital of Shanghai
-
Contact:
- Wei Zhang, MD
-
-
Zhejinag
-
Hangzhou, Zhejinag, China, 310009
- Recruiting
- SAHZU
-
Contact:
- Ying Yuan, Ph.D & MD
- Email: yuanying1999@zju.edu.cn
-
Contact:
- Ying Yuan
- Email: yuanying1999@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
20000 patients diagnosed with stage II-III colon cancer and undergo radical surgery since January 2010.
The demographic analysis of this study will include but limited in:
- Demographic characteristics (age, gender, height, weight),
- Clinical information (Site, TNM(Tumor, regional lymph Node, Metastasis) staging, CEA(Carcinoembryonic Antigen), imaging findings, patient ECOG(Eastern Cooperative Oncology Group)score, PS(Performance Status) score),
- Pathology information (MMR(Mismatch Repair) status, RAS status, BRAF status, HER2 status, Lymph node, Number of detections, Nerve infiltration, Vascular invasion, Histological type, etc.)
Description
Inclusion Criteria:
- Patients who are sick after January 2010
- Age is older than 18
- Surgical pathology confirmed TNM stage II-III (AJCC 7th edition) colon cancer
Exclusion Criteria:
- Combine other tumors
- Pathological information is not clear
- Researchers believe that other reasons are not suitable for enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with chemotherapy regimen for adjuvant therapy after stage II and stage III colon cancer
Time Frame: From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
|
Percentage of patients with chemotherapy regimen for adjuvant therapy after stage II and stage III colon cancer
|
From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
|
Percentage of patients with different chemotherapy time for adjuvant therapy for stage II and stage III colon cancer
Time Frame: From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
|
Percentage of patients with different chemotherapy time for adjuvant therapy for stage II and stage III colon cancer
|
From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
|
Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer
Time Frame: From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
|
Percentage of Participants with treatment-related Adverse Events as Assessed by CTCAE v4.0 for adjuvant therapy for stage II and stage III colon cancer
|
From patients after stage II and stage III colon cancer radical resection to until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2018
Primary Completion (Anticipated)
October 15, 2022
Study Completion (Anticipated)
December 15, 2023
Study Registration Dates
First Submitted
December 25, 2018
First Submitted That Met QC Criteria
May 19, 2019
First Posted (Actual)
May 22, 2019
Study Record Updates
Last Update Posted (Actual)
July 15, 2021
Last Update Submitted That Met QC Criteria
July 14, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REDUCE201809
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage II Colon Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedStage I Colon Cancer | Stage I Rectal Cancer | Stage II Colon Cancer | Stage II Rectal Cancer | Stage III Colon Cancer | Stage III Rectal CancerUnited States
-
Baylor College of MedicineGenentech, Inc.Not yet recruitingStage I Colon Cancer | Stage II Colon Cancer | Stage III Colon CancerUnited States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Rectum | Stage I Colon Cancer | Stage I Rectal Cancer | Stage II Colon Cancer | Stage II Rectal Cancer | Stage III Colon Cancer | Stage III Rectal Cancer | Adenocarcinoma of the ColonUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)Active, not recruitingFinancial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing TreatmentStage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Colon Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IIA Rectal Cancer AJCC... and other conditionsUnited States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
University of Roma La SapienzaAssociazione Italiana per la Ricerca sul CancroRecruitingColon Cancer Stage II | Colon Cancer Stage IIIItaly
-
Sohag UniversityActive, not recruitingColon Cancer Stage II | Colon Cancer Stage IEgypt
-
Mayo ClinicNational Cancer Institute (NCI)CompletedCancer Survivor | Stage I Breast Cancer AJCC v7 | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage II Colon Cancer | Stage III Colon CancerUnited States
-
Sun Yat-sen UniversityRecruitingColon Cancer Stage II | Colon Cancer Stage IIIChina